Laden…
7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one
Lorazepam is a benzodiazepine that primarily acts by enhancing GABA-A receptor activity. It is medically used for the treatment of anxiety disorders, sleep disturbances, and seizures. The substance possesses sedative, anxiolytic, and muscle-relaxant properties. Due to its potential for dependence, Lorazepam should only be used under medical supervision.
Class
Benzodiazepine
Pharmacological context
Mechanism
Lorazepam ist ein hochpotentes Benzodiazepin und positiv-allosterischer...
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
Interpret risks carefully
Condensed from structured notes
Receptor Targets
Mechanism of Action
Designations
IUPAC: Lorazepam
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Receptor Profile
Der GABA-A-Rezeptor ist ein ligandengesteuerter Chloridkanal und der wichtigste inhibitorische Rezeptor im zentralen Nervensystem. Er besitzt multiple allosterische Bindungsstellen für verschiedene Substanzklassen.
Synapedia Evidence
Effects & Pharmacology is partially translated. Some details are still being expanded.
Lorazepam ist ein hochpotentes Benzodiazepin und positiv-allosterischer Modulator von GABAA-Rezeptoren. Bindet an die Benzodiazepinbindungsstelle (zwischen α- und γ-Untereinheiten) und erhöht die Affinität von GABA für den Rezeptor, was den Cl⁻-Einstrom verstärkt (Hyperpolarisation). Im Gegensatz zu Diazepam: Konjugation durch direkte Glucuronidierung in der Leber (kein CYP450-Abbau) — dadurch weniger pharmakokinetische Interaktionen. Halbwertszeit 10-20h (intermediär). Kein aktiver Hauptmetabolit.
Known Effects
Individual effects may vary significantly. These are pharmacologically documented effects.
Reported range 1–2 mg
Total duration 6–8 hours
Oral
| Tier | Dosage |
|---|---|
| Light | 0.5–1 mg |
| Reported | 1–2 mg |
| Strong | 2–4 mg |
Oral
Onset
30–60 minutes
Peak
2–4 hours
Total duration
6–8 hours
After effects
2–4 hours
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Evidence
strong
Neurotoxicity
possible
Safer Use
Depressant-risk context
This substance belongs to a context where combinations with opioids, benzodiazepines, alcohol, GHB/GBL, or other sedating substances can increase sedation, blackout, aspiration, and breathing-risk patterns. Risk Check can review warning patterns; it is not medical advice and it cannot clear a combination as safe.
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.